For example, a recently published phase 2–3 study combining anti-LAG3 and anti-PD1 antibodies in melanoma patients reported 7/355 (2%) acute renal dysfunction [91], whereas this adverse events was not described in the original studies describing anti-CTLA4/anti-PD1 combination [92]. This evidence concerns the gene CTLA4 and melanoma.